I reviewed the attached manuscript from scratch as a JHIR Review article, including the literature-review methodology, all ten case studies, grounding analysis, limitations, conclusions, reproducibility material, declarations, and references. fileciteturn0file0L6-L6

## 1. SCIENTIFIC

The paper has a strong organizing idea, but in its current form I would expect substantive reviewer questions about the evidentiary status of both the “structured survey” and the ten application studies.

### Highest-impact scientific concerns

**1. The literature-review method is not sufficiently reproducible for the strength of the synthesis claims.**

Section 2 describes a “structured narrative review,” based on targeted searches of Google Scholar, arXiv, PubMed/MEDLINE, ACL Anthology, snowballing, and venue browsing, while explicitly acknowledging that it is non-exhaustive. fileciteturn1file0L304-L321 That is acceptable for a narrative Review article. The problem is that the manuscript then makes quantitative and near-exhaustive claims: counts of papers by task, claims that particular channels are “effectively absent,” and statements such as “No prior review organizes the field...” fileciteturn1file0L269-L300

For JHIR, I would add a compact reproducibility appendix/table giving search date(s), representative query strings, screening criteria, number of papers retained, duplicate handling, and a complete list of the reviewed corpus. You do not need to pretend this is PRISMA/systematic, but readers should be able to reconstruct what “the reviewed set” actually is. Absolute absence claims should become “we did not identify...” unless supported by a genuinely exhaustive search.

**2. The six-dimensional framework is more developed conceptually than empirically applied to the surveyed literature.**

The Introduction defines six useful dimensions: source grounding, channel, controlled properties, generation strategy, downstream task, and evaluation regime. fileciteturn1file0L229-L240 But Section 2 largely organizes evidence by task, and Table 6 is essentially a task/reference inventory. The manuscript never gives the reader the obvious central synthesis artifact: a study-by-study matrix showing the surveyed papers against those six dimensions.

This is probably the single largest missed opportunity in the Review component. Add one master table, perhaps in supplementary material if too large, with each included clinical paper as a row and the six framework dimensions as columns. That would turn the framework from a good conceptual diagram into the actual analytical machinery of the Review and directly answer RQ1–RQ6.

**3. Nine of ten case studies do not establish real-world utility.**

The manuscript handles this limitation much better than many synthetic-data papers: it explicitly states that nine studies are S→S, one is R+S→R, and none is pure S→R. fileciteturn2file0L14-L28 This candor is a strength.

However, the surrounding language is not always disciplined enough. A model that performs well on LLM-generated text generated under the same pipeline has demonstrated feasibility within that synthetic environment, not that the clinical channel “can be served,” that the system is “competent,” or that it will work on actual EMS, SBAR, portal, or postpartum communication.

For example, Section 3.2.1 concludes that the synthetic experiment indicates that a small local generator can bootstrap a “competent triage model.” Yet the evaluation is synthetic. That should become something like “a high-performing classifier on held-out synthetic messages under this generation protocol.” Keep that distinction absolutely consistent throughout.

**4. Potential source-level train/test leakage is insufficiently addressed.**

This is a major methodological concern. Several studies generate multiple synthetic realizations from the same underlying real source. In 3.1.1, 1,200 source descriptions are rewritten into multiple noise variants. In 3.3.1, 8,556 reports arise from 2,139 underlying MIMIC-IV-Ext cases—effectively multiple realizations per source case. The EMS results then compare clean/noisy training variants. fileciteturn1file1L918-L924

Table 20 says only that splits are “stratified 80/20.” fileciteturn5file1L25-L40 It does **not** state that all synthetic derivatives of the same underlying source were kept in the same partition. If sibling rewrites of one source appear in train and test, performance can be materially inflated.

The manuscript should explicitly state, for every multi-realization study, whether splitting occurred at the underlying patient/case/source level **before** generation. If it did, say so prominently. If not, the experiments require re-splitting.

**5. Study 3.1.2 is not reported as an empirical “application study” to the same standard as the other nine.**

The adaptive diagnostic-questioning section explains the simulation, reveal tiers, and information-gain objective, but supplies no actual diagnostic/questioning results: no number of episodes, models compared, questioning-efficiency values, accuracy by tier, uncertainty estimates, or result figure/table beyond the tier definitions. fileciteturn5file0L5-L18

That makes “ten application case studies” uneven. Either provide a compact results table for 3.1.2 or explicitly classify it as an illustrative benchmark instantiation rather than one of ten empirical case studies.

**6. The statistical presentation is inconsistent with the manuscript's seed-stability claim.**

Section 3 says the displayed values are single-run point estimates, then states that five-seed reruns demonstrate stability with SDs “typically below 0.05.” fileciteturn4file3L42-L49 The Data and Code section repeats that claim. fileciteturn4file4L58-L71

But the tables show mean±SD only selectively—for example, often for a classical baseline while the headline neural model remains a single number. That makes it unclear whether the five-seed sweep actually covers the exact headline models, simplified reproduction pipelines, or merely selected retrainable components.

If five-seed results already exist, report mean±SD for the headline stochastic models directly. If they do not, narrow the claim. “A reproducible pipeline is seed-stable” is not equivalent to “all reported headline metrics are seed-stable.”

Also, Section 2.3 calls macro-F1 “the right summary” for these tasks. fileciteturn1file0L491-L496 That is too categorical. Macro-F1 is useful under imbalance, but safety-oriented applications may require class-specific sensitivity/recall, precision, calibration, and clinically meaningful error costs. Use “a useful primary summary,” not “the right summary.”

**7. Synthetic labels are repeatedly called “gold” when many are not independently validated gold standards.**

If a prompt specifies “severe” and the LLM generates a severe-looking message, the specified class is an intended/source-derived label. It is not automatically gold, because the generated text may fail to express that label correctly. The manuscript itself recognizes this problem in the postpartum case.

This matters especially for clinical urgency, postpartum severity, SBAR completeness, and distress. Replace “gold label” with “target label,” “source-derived label,” or “reference label” unless expert adjudication actually establishes gold status.

**8. The medication-study augmentation interpretation needs more care.**

The important strength of 3.2.4 is that evaluation is on authentic patient-authored text. The weakness is causal attribution. The text says the SVM real-only baseline “isolates the real-only signal,” but the SVM differs from BioBERT/BlueBERT in both model architecture and training setup. Thus it cannot isolate the benefit of synthetic augmentation.

The strongest augmentation evidence appears to be GPT-4.1 classify-only versus generate+classify, 0.78 versus 0.85 macro-F1. For BioBERT/BlueBERT, a same-model real-only versus R+S ablation would be needed to claim the 0.90 performance is due to augmentation. Otherwise simply state that the encoders achieve 0.90 under R+S training.

**9. Same-generator evaluation bias deserves explicit case-level treatment.**

In the postpartum case, GPT-4o-mini generates the synthetic messages and is then evaluated zero-shot on those generated messages. The resulting 0.98 macro-F1 may partly reflect generator-specific linguistic regularities rather than clinical reasoning. The general limitations section mentions generator fingerprints, but this specific result deserves an explicit caveat.

A stronger design would use cross-generator or authentic testing. At minimum, do not present the near-equality between GPT-4o-mini and BioBERT as a clean model comparison without noting the provenance advantage.

**10. Reproducibility is good in intent but somewhat overclaimed in wording.**

Table 20 is valuable, but several studies ship only size-capped samples, and the medication study does not redistribute the synthetic augmentation. fileciteturn5file1L25-L40 Yet the text says “Every study ships a self-contained reproduction script” and implies full reproducibility. fileciteturn4file3L45-L49

Distinguish explicitly among:
- full regeneration/retraining reproduction;
- metric re-evaluation;
- reproduction on a size-capped sample;
- code-only reproduction requiring restricted source data/API access.

That would make the excellent provenance effort more credible rather than less.

### Ethics and provenance

A JHIR reviewer may also stop at the relationship between the original case studies and the article type. Section 2 says the studies were selected from graduate coursework. fileciteturn5file4L72-L77 The Acknowledgments say the students' projects “supplied the application studies.” fileciteturn3file4L43-L48 Yet the Author Contributions statement says the two authors “performed the analysis.” fileciteturn5file3L63-L65

This needs clarification, not necessarily because anything improper occurred, but because the provenance is unusual. State what the students did, what the authors independently reran/reanalyzed, how permission to reuse coursework was handled, and why acknowledgment rather than authorship/contributorship is appropriate.

Likewise, 3.2.4 involves 5,000 real patient-authored forum questions labeled by two reviewers. The blanket ethics statement “Not applicable” deserves more specificity: identify the public dataset status, whether content was already de-identified, and whether institutional policy classified secondary analysis as exempt/not human-subject research.

## 2. STYLISTIC & LANGUAGE

The manuscript is generally readable and considerably better organized than many broad LLM reviews, but several passages become promotional or overcompressed.

A few specific examples:

- **Introduction:** “the model does not invent clinical truth.” This is both stylistically absolute and scientifically inconsistent with the later hallucination discussion. fileciteturn3file0L5-L10 Better: “the source is intended to constrain the clinical facts, although the generator may still distort or hallucinate them.”

- **Section 2.1.1:** “each with its own characteristic way.” This is incomplete/awkward. Use “each with its own linguistic characteristics and failure modes.”

- **Section 2.2.1:** “underrepresented classes can be up-generated.” “Up-generated” is informal/nonstandard. Use “oversampled through targeted generation.”

- **Section 2.2.2:** “multi-agent play to voice it” is too conversational. Use “multi-agent simulation to realize the communication.”

- **Section 3.3.1:** “synthetic communication thus earns its value...” is promotional. Replace with a factual statement that noisy augmentation improved performance on the synthetic degraded test condition.

- **Section 3.2.5:** “fusing the two modalities wins” is informal. Use “the fusion model performs best.”

- **Conclusion:** “decisive” is repeated several times within a short paragraph—“One caveat is nonetheless decisive,” “the decisive evidence,” and “field's decisive next step.” fileciteturn4file2L29-L36 Reduce to one occurrence.

The longest Introduction paragraph combines seven RQs, the contribution statement, study positioning, and JHIR-fit framing in one dense block. fileciteturn1file0L250-L267 Split after the RQs; the contribution paragraph deserves to stand separately.

## 3. TONE

Overall tone is scholarly, but it oscillates between appropriately cautious caveats and advocacy for synthetic data.

The clearest example is privacy. Section 2.2 says synthetic text “can be shared, published, and reused without the consent and de-identification burdens” of real communication. fileciteturn3file1L17-L24 Section 4 later correctly says that assuming synthetic data is automatically safe is unfounded, that leakage remains possible, and that restricted-data governance can propagate into synthetic outputs. fileciteturn5file2L46-L57 The latter is the defensible position. Rewrite the earlier claim to say synthetic data **may reduce** privacy and access burdens when provenance, memorization, and governance are appropriately managed.

Similarly, “Clinical care runs on communication” is an effective opening, but statements such as “changed what is possible,” “decisively outperform,” “competent triage model,” “indispensable,” and “durable infrastructure” accumulate into a somewhat promotional register.

The paper is strongest when it uses the tone of Section 3.4: explicit about what the studies establish and what they do not. That tone should govern the entire manuscript.

## 4. INCONSISTENCIES

I found several concrete internal inconsistencies that should be corrected before submission.

**1. Home-care headline result is inconsistent.** Table 7 reports “LightGBM + TF-IDF fusion 0.97 F1.” fileciteturn3file3L32-L36 Section 3.2.5 reports **0.943±0.008 macro-F1** and 0.943±0.008 accuracy. fileciteturn4file1L18-L21 One is wrong or refers to a different metric. Fix Table 7 or explain the 0.97 statistic.

**2. The conclusion contradicts the abstract/Table 17 on real-data grounding.** The abstract and Section 3.4 correctly say four S→S studies are grounded in real datasets/records. Table 17 identifies studies 1, 2, 3, and 9. fileciteturn2file0L32-L45 But the Conclusion says that after the R+S→R medication study, “one further study” grounds generation in real clinical records, mentioning only EMS. fileciteturn4file2L29-L32 It should say that **four** synthetic-test studies use real source grounding, not one.

**3. “Nine of ten” channel claim appears numerically wrong.** Section 2.4 says “nine of the ten studies target portal messaging and these pre-hospital and handoff channels.” fileciteturn4file0L5-L11 Table 7 instead contains three studies in the patient–clinician/self-description group, five in Section 3.2, and two EMS/handoff studies. At most seven belong to the portal/pre-hospital/handoff grouping as described. Recalculate or rewrite.

**4. Model naming differs for SBAR.** Table 7 calls the model “ClinicalBERT,” while Section 3.3.2/Table 16 uses “BioClinicalBERT.” fileciteturn3file3L35-L35 Use one exact model name.

**5. The Introduction's “does not invent clinical truth” contradicts Section 4.1.** The former is categorical. fileciteturn3file0L5-L10 Section 4 explicitly says generators can hallucinate clinically wrong facts and corrupt labels. fileciteturn2file0L58-L76 This is more than wording; it is a conceptual contradiction.

## 5. GAPS

The largest missing elements for a JHIR Review article are:

**A study-level evidence matrix for the literature.** This should be the central table of the paper and map the reviewed literature onto the six framework dimensions.

**Transparent review search documentation.** Not PRISMA necessarily, but enough detail that “structured” is reproducible and the corpus counts are interpretable.

**Explicit source-group splitting/leakage controls** for case studies with multiple synthetic realizations per real source.

**A real results presentation for Study 3.1.2.** Currently it is a methodology vignette, not a fully reported application result.

**Label-validity reporting.** For clinically consequential fully synthetic tasks, state which labels were checked by humans, which by LLM judges, agreement rates where available, rejection rates, and what remained unvalidated.

**Better uncertainty reporting.** Since five-seed sweeps apparently already exist, use them consistently rather than defending single-run numbers.

**Clearer human/contributor provenance** for the graduate-course projects.

**A more specific ethics discussion** for the authentic medication-question corpus and student-derived research materials.

**Regulatory sourcing.** Section 4.2 makes broad statements such as “No current medical-device framework treats a synthetic training corpus as a distinct regulated object.” fileciteturn5file2L46-L49 That is jurisdiction-sensitive and should either receive authoritative regulatory citations and geographic scope or be softened substantially.

One smaller structural gap is that the taxonomy includes telemedicine and doctor-to-patient instructions, but the ten cases do not clearly instantiate either as distinct case-study channels. That is acceptable for an illustrative set, but Table 2 should not imply stronger case-study coverage than actually exists.

## Single most important improvement

**Make the framework genuinely operational by adding a reproducible study-level evidence matrix that maps the reviewed literature—and separately the ten cases—onto all six dimensions, including real-world evaluation regime.**

That one change would solve several current weaknesses simultaneously: it would justify calling this a structured Review, make RQ1–RQ6 visibly answered, differentiate literature evidence from the authors' case studies, expose where S→R evidence actually exists, and make the paper's contribution much clearer to a JHIR editor.

## Overall recommendation

**Major revision.**

I would put my current recommendation at roughly **65% major revision, 20% minor revision, 10% accept, 5% reject**. The paper has a publishable core and unusually explicit recognition of the synthetic-to-real validation gap, but it is not yet at clean-accept level because the Review methodology is insufficiently reproducible, the framework is not systematically applied to the literature, several case-study claims need tighter methodological qualification, and there are multiple concrete numerical/terminological inconsistencies.